Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC1R | Q01726 | 9/20 | 0.62 |
| ▸ | MC4R | P32245 | 9/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | IL2 | P60568 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MC5R | P33032 | 1/20 | 0.39 |
| ▸ | MC3R | P41968 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16188227 | 0.91 | MC1R (0.72) | MC1RMC4RKMT2AMC5RMC3R | |
| SCHEMBL16444996 | 0.90 | MC1R (0.70) | MC1RMC4RKMT2AMC5RMC3R | |
| SCHEMBL2148982 | 0.89 | MC1R (0.57) | MC1RMC4RKMT2A | |
| Trifluoroacetic Acid SCHEMBL1310165 | 0.84 | MC1R (0.49) | MC1RMC4R | |
| SCHEMBL16445574 | 0.83 | MC1R (0.61) | MC1RMC4RKMT2AITGB1ITGA4 | |
| SCHEMBL20450446 | 0.83 | MC1R (0.69) | MC1RMC4RKMT2AALBIL2 | |
| SCHEMBL1310104 | 0.83 | MC1R (0.69) | MC1RMC4RKMT2AALBIL2 | |
| SCHEMBL14360222 | 0.82 | MC1R (0.61) | MC1RMC4RKMT2A | |
| SCHEMBL1310666 | 0.82 | MC1R (0.47) | MC1RMC4RKMT2AGAAMMP3 | |
| SCHEMBL16445351 | 0.81 | MC1R (0.73) | MC1RMC4RKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342194-B1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-9630949-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-04-25 | — | — | US | disclosed |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | CYP51A1, TYR, CYP2C19 | MC1R 195/4885MC4R 873/4885KMT2A 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.